Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Melanoma treatment is being revolutionized by the development of effective immunotherapeutic approaches. These strategies include blockade of immune-inhibitory receptors on activated T cells; for example, using monoclonal antibodies against CTLA-4, PD-1, and PD-L1 (refs 3-5). However, only a subset of patients responds to these treatments, and data suggest that therapeutic benefit is preferentially achieved in patients with a pre-existing T-cell response against their tumour, as evidenced by a baseline CD8(+) T-cell infiltration within the tumour microenvironment. Understanding the molecular mechanisms that underlie the presence or absence of a spontaneous anti-tumour T-cell response in subsets of cases, therefore, should enable the development of therapeutic solutions for patients lacking a T-cell infiltrate. Here we identify a melanoma-cell-intrinsic oncogenic pathway that contributes to a lack of T-cell infiltration in melanoma. Molecular analysis of human metastatic melanoma samples revealed a correlation between activation of the WNT/β-catenin signalling pathway and absence of a T-cell gene expression signature. Using autochthonous mouse melanoma models we identified the mechanism by which tumour-intrinsic active β-catenin signalling results in T-cell exclusion and resistance to anti-PD-L1/anti-CTLA-4 monoclonal antibody therapy. Specific oncogenic signals, therefore, can mediate cancer immune evasion and resistance to immunotherapies, pointing to new candidate targets for immune potentiation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Tumor-intrinsic activation of the Wnt/β-catenin pathway (15) and deletion or mutation of Pten (16) have been shown to lead to deficient T cell infiltration into the tumor microenvironment and resistance to checkpoint blockade immunotherapy.”
From The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients (2018) · cites this paper as [15]
In the citing paper
“We reveal that the APOE variants exert cell-intrinsic effects on melanoma that impact primary tumor growth and metastatic capacity in a BrafV600E-driven GEMM, a model that has provided numerous important insights into melanoma biology (12,38–40).”
From Apolipoprotein E2 Stimulates Protein Synthesis and Promotes Melanoma Progression and Metastasis (2023) · cites this paper as [12]
In the citing paper
“Combinatorial biomarker strategies that capture attributes of the host and tumor-immune ecosystem will be essential (Fig. 2; refs.121-124).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [123]
In the citing paper
“For example, tumor cell-intrinsic WNT/β-catenin activation has been shown to lead to exclusion of T cells within the TME (123, 155, 156).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [123]
In the citing paper
“Mechanistic studies revealed that Wnt-induced decrease in the expression of the chemokine CCL4 hindered the recruitment of CD103+ DCs and T cells to the tumor microenvironment (Spranger et al., 2015).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Spranger et al., 2015
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Analyzing real-time PCR data by the comparative CT method
Schmittgen, T. D., & Livak, K. J. (2008) · Nature Protocols · doi:10.1038/nprot.2008.73 · Cited by 26,190
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
Wang, K., Li, M., & Hakonarson, H. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq603 · Cited by 14,621
An integrated map of genetic variation from 1,092 human genomes
The 1000 Genomes Project Consortium (2012) · Nature · doi:10.1038/nature11632 · Cited by 7,711
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking
Wilkerson, M. D., & Hayes, D. N. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq170 · Cited by 5,669
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Cited by
Items 201–300 of 1,015
Zheng, H., Zhao, W., Yan, C., Watson, C. C., Massengill, M., Xie, M., Massengill, C., Noyes, D. R., Martinez, G. V., Afzal, R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2584 · Cited by 340
Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets
Newell, F., Kong, Y., Wilmott, J. S., Johansson, P. A., Ferguson, P. M., Cui, C., Li, Z., Kazakoff, S. H., Burke, H., Dodds, T. J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11107-x · Cited by 334
Loh, J.-J., & Ma, S. (2024) · Cell Stem Cell · doi:10.1016/j.stem.2024.04.004 · Cited by 314
T cell receptor‐based cancer immunotherapy: Emerging efficacy and pathways of resistance
Chandran, S. S., & Klebanoff, C. A. (2019) · Immunological Reviews · doi:10.1111/imr.12772 · Cited by 323
Understanding the tumor microenvironment for effective immunotherapy
Sadeghi Rad, H., Monkman, J., Warkiani, M. E., Ladwa, R., O'Byrne, K., Rezaei, N., & Kulasinghe, A. (2021) · Medicinal Research Reviews · doi:10.1002/med.21765 · Cited by 334
“As such, they employed a tumor stroma‐targeting approach to deliver chemokine C‐C motif chemokine 4 (CCL4), a chemokine that has been shown to induce the recruitment of DCs, into tumors.(93,94) For this, a fusion protein of CCL4 and the collagen‐binding domain (CBD) of von Willebrand factor (VWF), a glycoprotein invol…”
BackgroundMethodWnt signaling pathways in biology and disease: mechanisms and therapeutic advances
Xue, C., Chu, Q., Shi, Q., Zeng, Y., Lu, J., & Li, L. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02142-w · Cited by 281
Dendritic cells as shepherds of T cell immunity in cancer
Pittet, M. J., Di Pilato, M., Garris, C., & Mempel, T. R. (2023) · Immunity · doi:10.1016/j.immuni.2023.08.014 · Cited by 313
Si, W., Liang, H., Bugno, J., Xu, Q., Ding, X., Yang, K., Fu, Y., Weichselbaum, R. R., Zhao, X., & Wang, L. (2022) · Gut · doi:10.1136/gutjnl-2020-323426 · Cited by 321
Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy
Zhai, L., Spranger, S., Binder, D. C., Gritsina, G., Lauing, K. L., Giles, F. J., & Wainwright, D. A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0420 · Cited by 322
“Interestingly, only a subset of patients have a T cell infiltrating presence within the tumor microenvironment, an observation reported for head and neck- and bladder-cancer, as well as melanoma, lung adenoma and glioblastoma (55).”
BackgroundSelf-citationGenetic profiling of hepatocellular carcinoma using next-generation sequencing
Schulze, K., Nault, J.-C., & Villanueva, A. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.035 · Cited by 317
Extended release of perioperative immunotherapy prevents tumor recurrence and eliminates metastases
Park, C. G., Hartl, C. A., Schmid, D., Carmona, E. M., Kim, H.-J., & Goldberg, M. S. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar1916 · Cited by 321
“We similarly observed increased numbers of CD8+ and CD103+ dendritic cells, which are crucial to cross-presentation and the production of robust antitumor immunity (29, 33), as well as B220+PDCA1+ (plasmacytoid dendritic cell antigen–1) plasmacytoid dendritic cells, which secrete large amounts of type I IFNs (Fig.”
BackgroundBrain Tumor Microenvironment and Host State: Implications for Immunotherapy
Tomaszewski, W., Sanchez-Perez, L., Gajewski, T. F., & Sampson, J. H. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1627 · Cited by 319
Self-citationEmerging Opportunities and Challenges in Cancer Immunotherapy
Whiteside, T. L., Demaria, S., Rodriguez-Ruiz, M. E., Zarour, H. M., & Melero, I. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0049 · Cited by 317
β-Catenin signaling in hepatocellular carcinoma
Xu, C., Xu, Z., Zhang, Y., Evert, M., Calvisi, D. F., & Chen, X. (2022) · Journal of Clinical Investigation · doi:10.1172/jci154515 · Cited by 305
“Likewise, activated β-catenin in melanoma cells enhances ATF3 expression and subsequently represses CCL4 expression, leading to reduced recruitment of dendritic cells and consequently T cells into the tumor tissues (142).”
Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases
Fischer, G. M., Jalali, A., Kircher, D. A., Lee, W.-C., McQuade, J. L., Haydu, L. E., Joon, A. Y., Reuben, A., de Macedo, M. P., Carapeto, F. C. L., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1489 · Cited by 329
Tissue-specific tumorigenesis: context matters
Schneider, G., Schmidt-Supprian, M., Rad, R., & Saur, D. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.5 · Cited by 311
Exploring the emerging role of the microbiome in cancer immunotherapy
Fessler, J., Matson, V., & Gajewski, T. F. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0574-4 · Cited by 319
Self-citationCancer-cell-derived GABA promotes β-catenin-mediated tumour growth and immunosuppression
Huang, D., Wang, Y., Thompson, J. W., Yin, T., Alexander, P. B., Qin, D., Mudgal, P., Wu, H., Liang, Y., Tan, L., et al. (2022) · Nature Cell Biology · doi:10.1038/s41556-021-00820-9 · Cited by 317
Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas
Schoenfeld, A. J., Rizvi, H., Bandlamudi, C., Sauter, J. L., Travis, W. D., Rekhtman, N., Plodkowski, A. J., Perez-Johnston, R., Sawan, P., Beras, A., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.01.065 · Cited by 324
“[36, 37] Meanwhile, pre-clinical and pre-clinical data support that STK11[11, 38–41] and WNT/β-catenin[15, 42, 43] signaling alterations are associated with an immunosuppressed tumor phenotype.”
PD-1/PD-L1 and immunotherapy for pancreatic cancer
Feng, M., Xiong, G., Cao, Z., Yang, G., Zheng, S., Song, X., You, L., Zheng, L., Zhang, T., & Zhao, Y. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.08.006 · Cited by 318
Demaria, S., Guha, C., Schoenfeld, J., Morris, Z., Monjazeb, A., Sikora, A., Crittenden, M., Shiao, S., Khleif, S., Gupta, S., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002038 · Cited by 301
“34 35 The degree of cDC1 infiltration in human tumors has also been associated with patient survival.”
CTLA-4 in Regulatory T Cells for Cancer Immunotherapy
Sobhani, N., Tardiel-Cyril, D. R., Davtyan, A., Generali, D., Roudi, R., & Li, Y. (2021) · Cancers · doi:10.3390/cancers13061440 · Cited by 303
Hepatocellular carcinoma: old friends and new tricks
Kim, E., & Viatour, P. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00527-1 · Cited by 307
Wang, F., Su, H., Xu, D., Dai, W., Zhang, W., Wang, Z., Anderson, C. F., Zheng, M., Oh, R., Wan, F., et al. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-020-0597-7 · Cited by 308
The role of dendritic cells in cancer and anti-tumor immunity
Marciscano, A. E., & Anandasabapathy, N. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101481 · Cited by 298
Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies
Passaro, A., Brahmer, J., Antonia, S., Mok, T., & Peters, S. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01845 · Cited by 303
Overcoming resistance to tumor-targeted and immune-targeted therapies
Aldea, M., Andre, F., Marabelle, A., Dogan, S., Barlesi, F., & Soria, J.-C. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1638 · Cited by 311
How chemokines organize the tumour microenvironment
Mempel, T. R., Lill, J. K., & Altenburger, L. M. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-023-00635-w · Cited by 281
“For instance, gain-of-function mutations in the gene encoding β-catenin or loss-of-function mutations in genes encoding its negative regulators are frequent and strongly correlated with poor T cell infiltration in human melanoma 203 .”
Immunity, Hypoxia, and Metabolism–the Ménage à Trois of Cancer: Implications for Immunotherapy
Riera-Domingo, C., Audigé, A., Granja, S., Cheng, W.-C., Ho, P.-C., Baltazar, F., Stockmann, C., & Mazzone, M. (2020) · Physiological Reviews · doi:10.1152/physrev.00018.2019 · Cited by 310
WNT Signaling and Colorectal Cancer
Schatoff, E. M., Leach, B. I., & Dow, L. E. (2017) · Current Colorectal Cancer Reports · doi:10.1007/s11888-017-0354-9 · Cited by 293
Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC
Gabrielson, A., Wu, Y., Wang, H., Jiang, J., Kallakury, B., Gatalica, Z., Reddy, S., Kleiner, D., Fishbein, T., Johnson, L., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0110 · Cited by 299
Migrating into the tumor: a roadmap for T cells
van der Woude, L. L., Gorris, M. A. J., Halilovic, A., Figdor, C. G., & de Vries, I. J. M. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.09.006 · Cited by 307
Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment
Saxena, M., & Bhardwaj, N. (2018) · Trends in Cancer · doi:10.1016/j.trecan.2017.12.007 · Cited by 305
The efficacy of anti‐PD‐1 agents in acral and mucosal melanoma
Shoushtari, A. N., Munhoz, R. R., Kuk, D., Ott, P. A., Johnson, D. B., Tsai, K. K., Rapisuwon, S., Eroglu, Z., Sullivan, R. J., Luke, J. J., et al. (2016) · Cancer · doi:10.1002/cncr.30259 · Cited by 302
“Future research into TILs and other immune subsets will help elucidate the mechanisms of resistance to immune surveillance, such as b-catenin signaling.(39) This, in turn, will help identify patients whose tumors will respond to PD-1 blockade and suggest rational combination strategies.”
BackgroundEnamorado, M., Iborra, S., Priego, E., Cueto, F. J., Quintana, J. A., Martínez-Cano, S., Mejías-Pérez, E., Esteban, M., Melero, I., Hidalgo, A., et al. (2017) · Nature Communications · doi:10.1038/ncomms16073 · Cited by 293
WNT Signaling in Tumors: The Way to Evade Drugs and Immunity
Martin-Orozco, E., Sanchez-Fernandez, A., Ortiz-Parra, I., & Ayala-San Nicolas, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02854 · Cited by 286
“This effect appears to be a consequence of the action of the negative regulatory pathway PD-L1-PD-1 (141).”
BackgroundOxidative Stress in the Tumor Microenvironment and Its Relevance to Cancer Immunotherapy
Aboelella, N. S., Brandle, C., Kim, T., Ding, Z.-C., & Zhou, G. (2021) · Cancers · doi:10.3390/cancers13050986 · Cited by 286
Spranger, S. (2016) · International Immunology · doi:10.1093/intimm/dxw014 · Cited by 290
Self-citationPD-1 and PD-L1 antibodies in cancer: current status and future directions
Balar, A. V., & Weber, J. S. (2017) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-017-1954-6 · Cited by 298
“1 3 appeared to be tumor intrinsic and mediated resistance to anti-PD-L1 and CTLA-4 therapy in autochthonous mouse melanoma models [81].”
BackgroundLee, J. H., Shklovskaya, E., Lim, S. Y., Carlino, M. S., Menzies, A. M., Stewart, A., Pedersen, B., Irvine, M., Alavi, S., Yang, J. Y. H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15726-7 · Cited by 288
Cancer immune evasion, immunoediting and intratumour heterogeneity
Roerden, M., & Spranger, S. (2025) · Nature Reviews Immunology · doi:10.1038/s41577-024-01111-8 · Cited by 265
“…immune evasion mechanisms and tissue-specific mechanisms of tolerance are associated with a lack of T cell infiltration (‘immune cold’ tumours) 30,38,39 , regional mechanisms restrict T cells to the tumour margins and local mechanisms do not interfere with T cell infiltration (‘immune hot’…”
InfluentialSelf-citationResistance to Checkpoint Inhibition in Cancer Immunotherapy
Barrueto, L., Caminero, F., Cash, L., Makris, C., Lamichhane, P., & Deshmukh, R. R. (2020) · Translational Oncology · doi:10.1016/j.tranon.2019.12.010 · Cited by 281
“Defects in this pathway causing activation of theWNT/β-catenin signaling pathway are correlated with acquired resistance to PD-1 blockade in patients with melanoma [47].”
BackgroundZhao, F., Xiao, C., Evans, K. S., Theivanthiran, T., DeVito, N., Holtzhausen, A., Liu, J., Liu, X., Boczkowski, D., Nair, S., et al. (2018) · Immunity · doi:10.1016/j.immuni.2017.12.004 · Cited by 289
“…studies, recent gene expression profiling based on microarray and RNA-seq datasets have demonstrated that primary melanomas, as well as other solid tumors, associated with a deficiency in TILs are associated with elevated b-catenin and PPAR-g signaling (Spranger et al., 2015; Sweis et al., 2016).”
Wnt Signaling and Its Significance Within the Tumor Microenvironment: Novel Therapeutic Insights
Patel, S., Alam, A., Pant, R., & Chattopadhyay, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02872 · Cited by 285
“On the contrary, β-catenin-active tumors do not react to anti-CTLA-4/anti-PD-1 immunotherapy (96).”
BackgroundAcquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression
Saleh, R., & Elkord, E. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.017 · Cited by 292
Metabolism shapes the tumor microenvironment
Reina-Campos, M., Moscat, J., & Diaz-Meco, M. (2017) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2017.05.006 · Cited by 293
WNT/β-Catenin Signaling Pathway Regulating T Cell-Inflammation in the Tumor Microenvironment
Li, X., Xiang, Y., Li, F., Yin, C., Li, B., & Ke, X. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02293 · Cited by 291
AP-1 Transcription Factors as Regulators of Immune Responses in Cancer
Atsaves, V., Leventaki, V., Rassidakis, G. Z., & Claret, F. X. (2019) · Cancers · doi:10.3390/cancers11071037 · Cited by 293
“A growing body of evidence indicate that activation of signaling pathways in various cancer types, such as the Mitogen-Activated Protein Kinases (MAPK) [8], phosphatidylinositol 3-kinase (PI3K) [9,10] and wnt/β-catenin [11] can promote an immune-compromised tumor microenvironment, conferring resistance to immunotherap…”
BackgroundTissue-resident memory T cells at the center of immunity to solid tumors
Amsen, D., van Gisbergen, K. P. J. M., Hombrink, P., & van Lier, R. A. W. (2018) · Nature Immunology · doi:10.1038/s41590-018-0114-2 · Cited by 278
Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics
Garg, A. D., More, S., Rufo, N., Mece, O., Sassano, M. L., Agostinis, P., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1386829 · Cited by 276
DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity
Lu, C., Guan, J., Lu, S., Jin, Q., Rousseau, B., Lu, T., Stephens, D., Zhang, H., Zhu, J., Yang, M., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.006 · Cited by 285
Mechanisms driving the immunoregulatory function of cancer cells
van Weverwijk, A., & de Visser, K. E. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00544-4 · Cited by 272
Gajewski, T. F., Corrales, L., Williams, J., Horton, B., Sivan, A., & Spranger, S. (2017) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-67577-0_2 · Cited by 278
Self-citationCombination therapy with immune checkpoint inhibitors (ICIs); a new frontier
Vafaei, S., Zekiy, A. O., Khanamir, R. A., Zaman, B. A., Ghayourvahdat, A., Azimizonuzi, H., & Zamani, M. (2022) · Cancer Cell International · doi:10.1186/s12935-021-02407-8 · Cited by 270
“As evidenced in melanoma, it appears that β-catenin activation could suppress the expression of chemokine chemokine (C–C motif ) ligands 4 (CCL4), which is mainly complicated in immune cell infiltration into TME [130, 131].”
BackgroundTargeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer
Hughes, P. E., Caenepeel, S., & Wu, L. C. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.04.010 · Cited by 282
“A systematic analysis of specific pathways that are associated with low levels of intratumoral T cell infiltrate has revealed that theWNT/b-catenin [107], PTEN/PI3K [108], and PPARg and FGFR3 pathways [109] are associated with exclusion of T cells from solid tumors and, in the case of the WNT/b-catenin and PTEN/PI3K p…”
BackgroundAntigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy
Sánchez-Paulete, A. R., Teijeira, A., Cueto, F. J., Garasa, S., Pérez-Gracia, J. L., Sánchez-Arráez, A., Sancho, D., & Melero, I. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx237 · Cited by 267
Promises and challenges of adoptive T-cell therapies for solid tumours
Morotti, M., Albukhari, A., Alsaadi, A., Artibani, M., Brenton, J. D., Curbishley, S. M., Dong, T., Dustin, M. L., Hu, Z., McGranahan, N., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01353-6 · Cited by 269
Kumar, V., Vashishta, M., Kong, L., Wu, X., Lu, J. J., Guha, C., & Dwarakanath, B. S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.650772 · Cited by 255
Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade
Gu, S. S., Zhang, W., Wang, X., Jiang, P., Traugh, N., Li, Z., Meyer, C., Stewig, B., Xie, Y., Bu, X., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0812 · Cited by 273
IFN-γ: A cytokine at the right time, is in the right place
Burke, J. D., & Young, H. A. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.05.002 · Cited by 254
Tumor Mutation Burden as a Biomarker in Resected Non–Small-Cell Lung Cancer
Devarakonda, S., Rotolo, F., Tsao, M.-S., Lanc, I., Brambilla, E., Masood, A., Olaussen, K. A., Fulton, R., Sakashita, S., McLeer-Florin, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.1963 · Cited by 272
Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma
Fankhauser, M., Broggi, M. A. S., Potin, L., Bordry, N., Jeanbart, L., Lund, A. W., Da Costa, E., Hauert, S., Rincon-Restrepo, M., Tremblay, C., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal4712 · Cited by 259
“In addition, several genes previously correlated with immunotherapy resistance, including CTNNB1 andMYC (24), were inversely correlated with VEGFC (Fig.”
BackgroundMethodImmunogenic cell death in anticancer chemotherapy and its impact on clinical studies
Wang, Q., Ju, X., Wang, J., Fan, Y., Ren, M., & Zhang, H. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.08.028 · Cited by 264
Okkenhaug, K., Graupera, M., & Vanhaesebroeck, B. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0716 · Cited by 264
Enterocolitis due to immune checkpoint inhibitors: a systematic review
Soularue, E., Lepage, P., Colombel, J. F., Coutzac, C., Faleck, D., Marthey, L., Collins, M., Chaput, N., Robert, C., & Carbonnel, F. (2018) · Gut · doi:10.1136/gutjnl-2018-316948 · Cited by 264
Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade
Jacquelot, N., Yamazaki, T., Roberti, M. P., Duong, C. P. M., Andrews, M. C., Verlingue, L., Ferrere, G., Becharef, S., Vétizou, M., Daillère, R., et al. (2019) · Cell Research · doi:10.1038/s41422-019-0224-x · Cited by 256
Hammerl, D., Martens, J. W. M., Timmermans, M., Smid, M., Trapman-Jansen, A. M., Foekens, R., Isaeva, O. I., Voorwerk, L., Balcioglu, H. E., Wijers, R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25962-0 · Cited by 262
Molecular Markers and Targets in Melanoma
Teixido, C., Castillo, P., Martinez-Vila, C., Arance, A., & Alos, L. (2021) · Cells · doi:10.3390/cells10092320 · Cited by 219
Chae, Y. K., Chang, S., Ko, T., Anker, J., Agte, S., Iams, W., Choi, W. M., Lee, K., & Cruz, M. (2018) · Scientific Reports · doi:10.1038/s41598-018-21061-1 · Cited by 253
Kumagai, S., Togashi, Y., Sakai, C., Kawazoe, A., Kawazu, M., Ueno, T., Sato, E., Kuwata, T., Kinoshita, T., Yamamoto, M., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.06.016 · Cited by 257
Ott, P. A., Piha-Paul, S. A., Munster, P., Pishvaian, M. J., van Brummelen, E. M. J., Cohen, R. B., Gomez-Roca, C., Ejadi, S., Stein, M., Chan, E., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx029 · Cited by 255
“This upregulation of PD-L1 is mediated by interferon-c secreted by T cells and has been termed ‘adaptive immune resistance’ [8, 20].”
BackgroundComprehensive molecular and immunological characterization of hepatocellular carcinoma
Shimada, S., Mogushi, K., Akiyama, Y., Furuyama, T., Watanabe, S., Ogura, T., Ogawa, K., Ono, H., Mitsunori, Y., Ban, D., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2018.12.058 · Cited by 257
“Three recent papers have reported the close correlation between functional mutation of β-catenin and potential exhaustion of immune cells including T cells [22,25,34] (Spranger et al.”
BackgroundClinical cancer immunotherapy: Current progress and prospects
Liu, C., Yang, M., Zhang, D., Chen, M., & Zhu, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.961805 · Cited by 249
WNT as a Driver and Dependency in Cancer
Parsons, M. J., Tammela, T., & Dow, L. E. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0190 · Cited by 257
The MYC oncogene is a global regulator of the immune response
Casey, S. C., Baylot, V., & Felsher, D. W. (2018) · Blood · doi:10.1182/blood-2017-11-742577 · Cited by 259
Woolston, A., Khan, K., Spain, G., Barber, L. J., Griffiths, B., Gonzalez-Exposito, R., Hornsteiner, L., Punta, M., Patil, Y., Newey, A., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.05.013 · Cited by 254
“The presence of BATF3 dendritic cells (DCs), which cross-present antigens from dying cancer cells to CD8 T cells, is critical for immunotherapy efficacy in melanoma (Spranger et al., 2015).”
BackgroundInflamed and non-inflamed classes of HCC: a revised immunogenomic classification
Montironi, C., Castet, F., Haber, P. K., Pinyol, R., Torres-Martin, M., Torrens, L., Mesropian, A., Wang, H., Puigvehi, M., Maeda, M., et al. (2023) · Gut · doi:10.1136/gutjnl-2021-325918 · Cited by 253
Menares, E., Gálvez-Cancino, F., Cáceres-Morgado, P., Ghorani, E., López, E., Díaz, X., Saavedra-Almarza, J., Figueroa, D. A., Roa, E., Quezada, S. A., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12319-x · Cited by 237
Hoch, T., Schulz, D., Eling, N., Gómez, J. M., Levesque, M. P., & Bodenmiller, B. (2022) · Science Immunology · doi:10.1126/sciimmunol.abk1692 · Cited by 250
Hallmarks of response to immune checkpoint blockade
Cogdill, A. P., Andrews, M. C., & Wargo, J. A. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.136 · Cited by 238
“…with signals derived from tumour cells preventing immune infiltration (e.g., Wnt-b-catenin, PPAR-g, FGFR3) while the dynamic interplay of anti-tumour immune attack adaptively moulds the landscape of immunomodulatory elements present over time (Spranger et al, 2013, 2015; Sweis et al, 2016).”
BackgroundKatoh, M. (2018) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2018.3689 · Cited by 211
“1c) include ABCB1, ALDH1A1, ASCL2, ATF3, AXIN2, BAMBI, CCND1 (Cyclin D1) , CD44, Claudin‑1 (CLDN1), CTLA4, DKK1, EDN1, EOMES, FGF18, FGF20, FZD7, GBX1, IL10 (IL‑10), Jagged‑1 (JAG1) , LEF1, LGR5 , MITF , MSX1, MYC (c‑Myc), NEUROD1 , NKD1 , NODAL, NOTCH2, NOTUM, NRCAM, osteopontin (OPN), PAX3, PPARD , PTGS2 ( COX2), RN…”
Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review
Khan, S., & Gerber, D. E. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.06.012 · Cited by 241
Tumor-infiltrating dendritic cell states are conserved across solid human cancers
Gerhard, G. M., Bill, R., Messemaker, M., Klein, A. M., & Pittet, M. J. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20200264 · Cited by 247
“Conservation of tumor-infiltrating dendritic cells https://doi.org/10.1084/jem.20200264 CXCL9 (Chow et al., 2019) and CXCL10 (Spranger et al., 2017) that recruit CD8+ T cells to tumors and enable local (re)activation of these cells through antigen cross-presentation (Spranger et al., 2017; Chow et al., 2019), and thro…”
BackgroundInfluentialMechanisms of immune activation and regulation: lessons from melanoma
Kalaora, S., Nagler, A., Wargo, J. A., & Samuels, Y. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00442-9 · Cited by 240
“58 ) , and the prevention of T cell priming to antitumour responses by disrupting the recruitment of DCs expressing the transcription factor BATF3 (reFs 59,60 ) .”
BackgroundImmune Exclusion-Wnt/CTNNB1 Class Predicts Resistance to Immunotherapies in HCC
Pinyol, R., Sia, D., & Llovet, J. M. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3778 · Cited by 249
“These results are in line with the seminal study in melanoma demonstrating that non–T-cell–inflamed phenotype displayed altered b-catenin signaling (7).”
BackgroundResultJiménez-Sánchez, A., Cybulska, P., Mager, K. L., Koplev, S., Cast, O., Couturier, D.-L., Memon, D., Selenica, P., Nikolovski, I., Mazaheri, Y., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-0630-5 · Cited by 243
Vilain, R. E., Menzies, A. M., Wilmott, J. S., Kakavand, H., Madore, J., Guminski, A., Liniker, E., Kong, B. Y., Cooper, A. J., Howle, J. R., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0698 · Cited by 245
Ferris, R. L., Spanos, W. C., Leidner, R., Gonçalves, A., Martens, U. M., Kyi, C., Sharfman, W., Chung, C. H., Devriese, L. A., Gauthier, H., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002568 · Cited by 228
PRMT5 control of cGAS/STING and NLRC5 pathways defines melanoma response to antitumor immunity
Kim, H., Kim, H., Feng, Y., Li, Y., Tamiya, H., Tocci, S., & Ronai, Z. A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz5683 · Cited by 232
“Homozygous deletion of B2M, encoding the subunit (2- microglobulin) for all human leukocyte antigen (HLA) class I complexes, impairs antigen processing and presentation by tumor cells, contributing to resistance to ICT in melanoma and lung cancer (9, 10).”
BackgroundInfluentialA microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers
Fidelle, M., Rauber, C., Alves Costa Silva, C., Tian, A.-L., Lahmar, I., de La Varende, A.-L. M., Zhao, L., Thelemaque, C., Lebhar, I., Messaoudene, M., et al. (2023) · Science · doi:10.1126/science.abo2296 · Cited by 243
“, A novel endothelial L-selectin ligand activity in lymph node medulla that is regulated by alpha(1,3)fucosyltransferase-IV.”
BackgroundWnt Signaling and Drug Resistance in Cancer
Zhong, Z., & Virshup, D. M. (2020) · Molecular Pharmacology · doi:10.1124/mol.119.117978 · Cited by 241
“Activation of tumor intrinsic b-catenin signaling suppresses the expression of tumor-cell–intrinsic chemokines such as CCL4, thereby suppressing the recruitment of CD1031 dendritic cells and subsequent activation of CD81 T-cells (Spranger et al., 2015).”
BackgroundWNT Signaling in Cancer Immunosurveillance
Galluzzi, L., Spranger, S., Fuchs, E., & López-Soto, A. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.08.005 · Cited by 239
Self-citationTreg-mediated acquired resistance to immune checkpoint inhibitors
Saleh, R., & Elkord, E. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.05.003 · Cited by 236
Exploiting innate immunity for cancer immunotherapy
Yi, M., Li, T., Niu, M., Mei, Q., Zhao, B., Chu, Q., Dai, Z., & Wu, K. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01885-w · Cited by 225
Metabolic Control of CD8+ T Cell Fate Decisions and Antitumor Immunity
Zhang, L., & Romero, P. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.11.005 · Cited by 235
Wnt signaling pathway in cancer immunotherapy
Zhou, Y., Xu, J., Luo, H., Meng, X., Chen, M., & Zhu, D. (2022) · Cancer Letters · doi:10.1016/j.canlet.2021.10.034 · Cited by 233
Kwon, M., An, M., Klempner, S. J., Lee, H., Kim, K.-M., Sa, J. K., Cho, H. J., Hong, J. Y., Lee, T., Min, Y. W., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0219 · Cited by 237
Riesenberg, S., Groetchen, A., Siddaway, R., Bald, T., Reinhardt, J., Smorra, D., Kohlmeyer, J., Renn, M., Phung, B., Aymans, P., et al. (2015) · Nature Communications · doi:10.1038/ncomms9755 · Cited by 227
Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy
Gnjatic, S., Bronte, V., Brunet, L. R., Butler, M. O., Disis, M. L., Galon, J., Hakansson, L. G., Hanks, B. A., Karanikas, V., Khleif, S. N., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0243-4 · Cited by 228
“affecting the antigen presentation machinery [178, 179], or the local recruitment of immune actors [180, 181] all”
BackgroundClinical cancer genomic profiling
Chakravarty, D., & Solit, D. B. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00338-8 · Cited by 226
Metadata
- Authors
- Spranger, S., Bao, R., & Gajewski, T. F.
- Affiliations
- University of Chicago (US)
- Corresponding author
- Gajewski, Thomas F.
- Venue
- Nature
- Published
- 2015-05-11
- Volume
- 523
- Issue
- 7559
- Pages
- 231-235
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1498931318
- Cited by
- 2,830
- References
- 45
- Citations by year
- 2026: 240 · 2025: 234 · 2024: 222 · 2023: 270 · 2022: 319 · 2021: 367 · 2020: 337 · 2019: 246 · 2018: 198 · 2017: 212 · 2016: 151 · 2015: 31
- FWCI
- 86.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- melanoma, β-catenin signaling, Wnt signaling, cancer immunotherapy resistance, PD-L1 blockade, CTLA-4 blockade, T-cell exclusion, tumor microenvironment, CD8+ T cell infiltration, tumor immune evasion, oncogenic signaling, immune checkpoint blockade
- MeSH terms
- Animals, Humans, Immunotherapy, Melanoma, T-Lymphocytes, Signal Transduction, Gene Expression Regulation, Neoplastic, Gene Expression Profiling, Wnt Proteins, beta Catenin, Mice, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.